Online inquiry

IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11273MR)

This product GTTS-WQ11273MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11273MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5043MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ2103MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ13497MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ10571MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9085MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ4605MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ11993MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ13852MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW